Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tuberculosis Blood Test Recommended For Key Groups

By LabMedica International staff writers
Posted on 12 Apr 2011
A blood test for latent tuberculosis infection (LTBI) should be the primary test in certain suspect groups suggests a recent official recommendation. More...


The innovative blood test, called the interferon-gamma release assay (IGRAs), is now thought to be more reliable than the Mantoux Tuberculin Sensitivity technique especially where the individual has already been vaccinated or was skin test positive.

In recognition of the mounting clinical evidence in favor of IGRA technology, the UK National Institute for Health and Clinical Excellence (NICE; London, UK), recommend directly using an IGRA blood test in a number of specified instances. These include: in an outbreak situation when large numbers of individuals may need to be screened; recent arrivals from high incidence countries who are from 16 to 34 years old; the immunocompromised and some people with human immunodeficiency virus (HIV); new health service employees who have recently arrived from high incidence countries or who have had contact with patients in a setting where tuberculosis is highly prevalent.

These interventions are designed to identify subjects with LTBI so that they can be treated before they convert to active disease. This proactive approach will help to reduce the rates of active TB disease in the UK, which have been rising over the past decade. The IGRA blood test is produced by Oxford Immunotec (Marlborough, MA, USA) and sold under the name T-SPOT.TB test.

Peter Wrighton-Smith, PhD, CEO of Oxford Immunotec, said, "I very much welcome the new guidelines from NICE which recognize the superior accuracy and convenience of IGRA testing in many populations. I am optimistic that the adoption of these guidelines will help to reverse the steadily increasing rates of TB seen in the UK over the past decade." The T-SPOT.TB test is approved for sale in Europe, USA, Canada, and over 40 other countries worldwide and is designed to replace the 115-year-old tuberculin skin test. It offers a substantially more accurate and effective tool for controlling the spread of TB.

Related Links:
UK National Institute for Health and Clinical Excellence
Oxford Immunotec



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.